• Emory University, B.A. biology and sociology
  • Mercer University School of Pharmacy, Pharm.D., magna cum laude
  • University of Maryland School of Law, J.D., with honors


  • District of Columbia
  • Maryland
  • Utah
  • U.S. Patent and Trademark Office (USPTO)
  • Supreme Court of the United States
  • Utah Supreme Court
  • U.S. District Court, District of Utah
  • Maryland Court of Appeals

Professional Experience

  • MYLAN, N.V.
    Vice President, Global IP Strategy, August 2013–December 2015
  • Actavis, Inc.
    Senior Intellectual Property Counsel, March 2011–August 2013
    Intellectual Property Counsel, September 2004–March 2011
    Associate Director, Intellectual Property, August 2002–September 2004 
  • Chesapeake Biological Laboratories, Inc.
    Program Director, Formulation, June 2001–June 2002 
  • Clinical Pharmacist
    January 1994–January 1999 
  • Roche Pharmaceuticals
    Drug Information Resident, August 1993–January 1994

Kent M. Walker, Pharm.D.

Senior Counsel

When pharmaceutical and biotech clients need experience, creativity, and value, they turn to Kent Walker for solutions to successfully navigate intellectual property and regulatory issues to drive their products to market on time.

Kent has more than 25 years of experience in pharmaceutical- and biotechnology-related industries as a pharmacist, researcher, and attorney. His extensive experience as in-house counsel at major pharmaceutical companies gives him the ability to blend a technical and legal focus with an eye to achieving optimal commercial outcomes in his counseling. Kent is known for his ability to analyze issues thoroughly and to guide clients to a strategy that will set them up for success.

Kent focuses his practice on helping pharmaceutical and biotechnology companies develop products and bring them to market through counseling and litigation. Prior to joining Crowell & Moring, he spent over 15 years as senior counsel at Actavis Plc and was vice president of global IP strategy at Mylan, where he developed and managed the litigation of hundreds of pharmaceutical and biosimilar products and was responsible for implementing strategies that are widely used throughout the industry today.

In addition to his primary focus, Kent has represented clients, including software companies and famous athletes, in a broad array of matters, including licensing, brand protection, and commercial disputes.

Representative Matters

  • Genentech, Inc. v. Tanvex BioPharma USA, et al. Serving as lead counsel for a biosimilar company in BPCIA litigation concerning the anti-cancer agent trastuzumab.
  • Advised a major biotech company on prelitigation strategy for a biosimilar to a blockbuster oncology monoclonal antibody.
  • Otsuka Pharmaceutical Co. et al. v. Amneal Pharmaceuticals, LLC, et al. Served as lead counsel representing multiple ANDA applicants and successfully negotiated an early entry date for the client after expert discovery.
  • Richard Glossip, et al., v. Randy Chandler, et al. Served as second chair at a trial representing Oklahoma death row inmates in their Eighth Amendment challenge to Oklahoma’s lethal injection protocol.
  • Celgene Corporation (Amgen Inc.) v. Sandoz Inc., et al. Served as lead counsel to Amneal Pharmaceuticals  in a Hatch-Waxman litigation concerning the antidepressant Rexulti  and negotiated an early market entry date during the pretrial phase of the case.
  • Vifor AG and American, Inc. v. Sandoz Inc. Served as co-counsel through trial and ultimately obtained a favorable settlement for the client prior to a final decision.
  • Janssen Products, L.P., et al. v. Amneal Pharmaceuticals, LLC, et al. Served as lead counsel.
  • Whynotapparrel, LLC v. Nike, Inc. Served as lead plaintiff’s counsel and negotiated the sale of the plaintiff’s IP to a related third party.
  • Astellas Pharma et al. v. Windlas Biotech Ltd. et al. Served as lead counsel.

Press Coverage